{"title": "Gwynn Douglas Long", "author": null, "url": null, "hostname": null, "description": "Gwynn Douglas Long | Scholars@Duke profile: Publications", "sitename": null, "date": "1995-01-01", "cleaned_text": "Selected Publications Journal Article Transplant Cell Ther \u00b7 March 2023 Despite the exciting advancement of novel therapies, chronic graft-versus-host disease (cGVHD) remains the most common cause of non-relapse mortality after allogeneic hematopoietic stem cell transplantation (HCT). Frontline treatment of cGVHD syst ... [A Phase I Trial of SYK Inhibition with Fostamatinib in the Prevention and Treatment Disease. ](/publication/1560448) [Full text](https://dx.doi.org/10.1016/j.jtct.2022.12.015) [Link to item](https://www.ncbi.nlm.nih.gov/pubmed/36577483) Ann Hematol \u00b7 February 2023 Multiple myeloma (MM) remains an incurable disease and there is an unmet medical need for novel therapeutic drugs that do not share similar mechanisms of action with currently available agents. Sphingosine kinase 2 (SK2) is an innovative molecular target f ... [Phase I study of opaganib, an oral to Marrow Transplant \u00b7 December 2022 [Revisiting a single day salvage conditioning following graft failure. ](/publication/1553280) [Full text](https://dx.doi.org/10.1038/s41409-022-01832-1) [Link to item](https://www.ncbi.nlm.nih.gov/pubmed/36182986) August 2022 Allogeneic hematopoietic stem cell transplantation (HCT) is a potentially curative treatment for both malignant and nonmalignant hematologic diseases; however, reported rates of treatment-related mortality approach 30%. Outcomes are worse in patients who b ... [Geriatric Assessment Reveals Actionable Impairments in Hematopoietic Stem Cell Transplantation Candidates Age 18 to 80 Years. ](/publication/1521437) [Full text](https://dx.doi.org/10.1016/j.jtct.2022.05.018) [Link to item](https://www.ncbi.nlm.nih.gov/pubmed/35595226) [Cite](/publication/1521437#cite) Journal 2022 Patients undergoing allogeneic (allo) and autologous (auto) hematopoietic cell transplantation (HCT) require extensive hospitalizations or daily clinic visits for the duration of their transplantation. Home HCT, wherein patients live at home and providers ... [Home-Based Hematopoietic Cell Transplantation in text](https://dx.doi.org/10.1016/j.jtct.2022.01.015) [Link to item](https://www.ncbi.nlm.nih.gov/pubmed/35066211) [Cite](/publication/1506925#cite) Conference \u00b7 January 2022 Hematopoietic cell transplant (HCT) is an increasingly common and curative treatment strategy to improve survival among individuals with malignant and nonmalignant diseases, with over one million HCTs having been performed worldwide. Neurocognitive dysfunc ... [Cognitive impairment [Full Journal Article Transplant Cell Ther \u00b7 September 2021 Life expectancy for long-term survivors of allogeneic hematopoietic stem cell transplantation (alloHSCT), defined as those living 5 years post-transplantation, is significantly lower compared with that of the age-matched general population despite a relat ... [Female Sex Is Associated with Improved Long-Term Survival Allogeneic Hematopoietic Stem Cell Transplantation. ](/publication/1485675) [Full August 2021 Allogeneic hematopoietic stem cell transplantation (HCT) has the potential to cure hematologic malignancies but is associated with significant morbidity and mortality. Although deaths during the first year after transplantation are often attributable to tr ... [Decreased Mortality in 1-Year Survivors of Umbilical Cord Blood Transplant vs. Matched Related or Matched Unrelated Donor Transplant in Patients with J \u00b7 May 16, 2021 [Morphologic leukemia-free state in acute myeloid leukemia is sufficient \u00b7 March 2021 Bloodstream infections (BSIs) occur autologous and allogeneic hematopoietic with the antiseptic chlorhexidine gluconate (CHG) has been shown to of BSIs in critica ... [Chlorhexidine Gluconate Bathing Reduces the Incidence of Bloodstream Infections in Adults Undergoing Inpatient Hematopoietic Cell Transplantation. ](/publication/1475394) [Full \u00b7 February 2021 Hematopoietic stem cell transplantation (HCT) is a curative treatment option for patients with hematologic conditions but presents many complications that must be managed as a complex, chronic condition. Mobile health applications (mHealth apps) may permit ... [Assessing the Feasibility of a Novel mHealth App in Hematopoietic Stem Cell Transplant Patients. ](/publication/1475300) [Full text](https://dx.doi.org/10.1016/j.jtct.2020.10.017) [Link to item](https://www.ncbi.nlm.nih.gov/pubmed/33830035) [Cite](/publication/1475300#cite) Journal January 2021 Prophylactic donor lymphocyte infusions (DLI) are used to augment post-transplant immune recovery to reduce both infectious complications and disease recurrence. Preclinical studies implicate the naive T-cell subset as the primary driver of graft-versus-ho ... [Phase I dose escalation study of naive T-cell depleted donor lymphocyte infusion following allogeneic Allogeneic hematopoietic stem cell transplantation (HCT) is an often curative intent treatment, however it is associated with significant gastrointestinal (GI) toxicity and treatment related mortality. Graft-versus-host disease is a significant ... [A phase 2 trial of the somatostatin analog pasireotide to prevent GI toxicity and acute GVHD in allogeneic [Cite](/publication/1487527#cite) Journal Article Biol Blood Marrow Transplant \u00b7 December 2020 Delirium is common among adults undergoing hematopoietic stem cell transplantation (HCT), although the clinical and neuroimaging correlates of post-HCT delirium have not been adequately delineated. We therefore examined the frequency of delirium and \u00b7 March 24, 2020 Human cytomegalovirus (HCMV) can cause significant disease in immunocompromised patients, and treatment options are limited by toxicities. CSJ148 is a combination of two anti-HCMV human monoclonal antibodies (LJP538 and LJP539) that bind to and inhibit the ... [Phase 2 Study of Anti-Human Cytomegalovirus \u00b7 2020 Allogeneic-HCT (allo-HCT), while potentially curative, can result in significant complications including graft versus host disease (GVHD). Prior studies suggest that metabolic syndrome may be one risk factor for GVHD. that hepatic steatosis ... liver) mortality. ](/publication/1459192) 2019 chronic graft-vs-host disease (cGVHD) is common after allogeneic hematopoietic stem cell transplant and is often associated with poor patient outcomes. A reliable and practical method for assessing disease severity and response to the ... [Interrater Reliability of Clinical Grading to item](https://www.ncbi.nlm.nih.gov/pubmed/30994873) [Cite](/publication/1380923#cite) Journal Blood J \u00b7 July 31, 2018 [Bendamustine, pomalidomide, and dexamethasone to item](https://www.ncbi.nlm.nih.gov/pubmed/30065277) \u00b7 January 2018 Single-agent high-dose melphalan (HDM, 200 mg/m2) has been the most commonly used conditioning regimen prior to autologous stem cell transplant, since its introduction in 1992. We used a more aggressive alkylator-based conditioning regimen in an attempt to ... [High-dose BCNU/Melphalan conditioning regimen before autologous stem cell multiple myeloma. December 2017 We retrospectively studied 340 fit patients with multiple myeloma (MM) who underwent autologous stem cell transplantation (ASCT). We hypothesized that progression-free survival (PFS) of older patients was non-inferior to that of younger patients after ASCT ... [Efficacy and safety of high-dose chemotherapy with autologous stem cell transplantation in senior versus younger adults with newly diagnosed multiple myeloma. ](/publication/1169768) [Full text](https://dx.doi.org/10.1002/hon.2379) [Link to item](https://www.ncbi.nlm.nih.gov/pubmed/28105753) [Cite](/publication/1169768#cite) Journal Article Transplant Cell Ther \u00b7 March 2023 Despite the exciting advancement of novel therapies, chronic graft-versus-host disease (cGVHD) remains the most common cause of non-relapse mortality after allogeneic hematopoietic stem cell transplantation (HCT). Frontline treatment of cGVHD syst ... [A Phase I Trial of SYK Inhibition with Fostamatinib in the Prevention and Treatment Disease. ](/publication/1560448) [Full text](https://dx.doi.org/10.1016/j.jtct.2022.12.015) [Link to item](https://www.ncbi.nlm.nih.gov/pubmed/36577483) Ann Hematol \u00b7 February 2023 Multiple myeloma (MM) remains an incurable disease and there is an unmet medical need for novel therapeutic drugs that do not share similar mechanisms of action with currently available agents. Sphingosine kinase 2 (SK2) is an innovative molecular target f ... [Phase I study of opaganib, an oral to Marrow Transplant \u00b7 December 2022 [Revisiting a single day salvage conditioning following graft failure. ](/publication/1553280) [Full text](https://dx.doi.org/10.1038/s41409-022-01832-1) [Link to item](https://www.ncbi.nlm.nih.gov/pubmed/36182986) August 2022 Allogeneic hematopoietic stem cell transplantation (HCT) is a potentially curative treatment for both malignant and nonmalignant hematologic diseases; however, reported rates of treatment-related mortality approach 30%. Outcomes are worse in patients who b ... [Geriatric Assessment Reveals Actionable Impairments in Hematopoietic Stem Cell Transplantation Candidates Age 18 to 80 Years. ](/publication/1521437) [Full text](https://dx.doi.org/10.1016/j.jtct.2022.05.018) [Link to item](https://www.ncbi.nlm.nih.gov/pubmed/35595226) [Cite](/publication/1521437#cite) Journal 2022 Patients undergoing allogeneic (allo) and autologous (auto) hematopoietic cell transplantation (HCT) require extensive hospitalizations or daily clinic visits for the duration of their transplantation. Home HCT, wherein patients live at home and providers ... [Home-Based Hematopoietic Cell Transplantation in text](https://dx.doi.org/10.1016/j.jtct.2022.01.015) [Link to item](https://www.ncbi.nlm.nih.gov/pubmed/35066211) [Cite](/publication/1506925#cite) Conference \u00b7 January 2022 Hematopoietic cell transplant (HCT) is an increasingly common and curative treatment strategy to improve survival among individuals with malignant and nonmalignant diseases, with over one million HCTs having been performed worldwide. Neurocognitive dysfunc ... [Cognitive impairment [Full Journal Article Transplant Cell Ther \u00b7 September 2021 Life expectancy for long-term survivors of allogeneic hematopoietic stem cell transplantation (alloHSCT), defined as those living 5 years post-transplantation, is significantly lower compared with that of the age-matched general population despite a relat ... [Female Sex Is Associated with Improved Long-Term Survival Allogeneic Hematopoietic Stem Cell Transplantation. ](/publication/1485675) [Full August 2021 Allogeneic hematopoietic stem cell transplantation (HCT) has the potential to cure hematologic malignancies but is associated with significant morbidity and mortality. Although deaths during the first year after transplantation are often attributable to tr ... [Decreased Mortality in 1-Year Survivors of Umbilical Cord Blood Transplant vs. Matched Related or Matched Unrelated Donor Transplant in Patients with J \u00b7 May 16, 2021 [Morphologic leukemia-free state in acute myeloid leukemia is sufficient \u00b7 March 2021 Bloodstream infections (BSIs) occur autologous and allogeneic hematopoietic with the antiseptic chlorhexidine gluconate (CHG) has been shown to of BSIs in critica ... [Chlorhexidine Gluconate Bathing Reduces the Incidence of Bloodstream Infections in Adults Undergoing Inpatient Hematopoietic Cell Transplantation. ](/publication/1475394) [Full \u00b7 February 2021 Hematopoietic stem cell transplantation (HCT) is a curative treatment option for patients with hematologic conditions but presents many complications that must be managed as a complex, chronic condition. Mobile health applications (mHealth apps) may permit ... [Assessing the Feasibility of a Novel mHealth App in Hematopoietic Stem Cell Transplant Patients. ](/publication/1475300) [Full text](https://dx.doi.org/10.1016/j.jtct.2020.10.017) [Link to item](https://www.ncbi.nlm.nih.gov/pubmed/33830035) [Cite](/publication/1475300#cite) Journal January 2021 Prophylactic donor lymphocyte infusions (DLI) are used to augment post-transplant immune recovery to reduce both infectious complications and disease recurrence. Preclinical studies implicate the naive T-cell subset as the primary driver of graft-versus-ho ... [Phase I dose escalation study of naive T-cell depleted donor lymphocyte infusion following allogeneic Allogeneic hematopoietic stem cell transplantation (HCT) is an often curative intent treatment, however it is associated with significant gastrointestinal (GI) toxicity and treatment related mortality. Graft-versus-host disease is a significant ... [A phase 2 trial of the somatostatin analog pasireotide to prevent GI toxicity and acute GVHD in allogeneic [Cite](/publication/1487527#cite) Journal Article Biol Blood Marrow Transplant \u00b7 December 2020 Delirium is common among adults undergoing hematopoietic stem cell transplantation (HCT), although the clinical and neuroimaging correlates of post-HCT delirium have not been adequately delineated. We therefore examined the frequency of delirium and \u00b7 March 24, 2020 Human cytomegalovirus (HCMV) can cause significant disease in immunocompromised patients, and treatment options are limited by toxicities. CSJ148 is a combination of two anti-HCMV human monoclonal antibodies (LJP538 and LJP539) that bind to and inhibit the ... [Phase 2 Study of Anti-Human Cytomegalovirus \u00b7 2020 Allogeneic-HCT (allo-HCT), while potentially curative, can result in significant complications including graft versus host disease (GVHD). Prior studies suggest that metabolic syndrome may be one risk factor for GVHD. that hepatic steatosis ... liver) mortality. ](/publication/1459192) 2019 chronic graft-vs-host disease (cGVHD) is common after allogeneic hematopoietic stem cell transplant and is often associated with poor patient outcomes. A reliable and practical method for assessing disease severity and response to the ... [Interrater Reliability of Clinical Grading to item](https://www.ncbi.nlm.nih.gov/pubmed/30994873) [Cite](/publication/1380923#cite) Journal Blood J \u00b7 July 31, 2018 [Bendamustine, pomalidomide, and dexamethasone to item](https://www.ncbi.nlm.nih.gov/pubmed/30065277) \u00b7 January 2018 Single-agent high-dose melphalan (HDM, 200 mg/m2) has been the most commonly used conditioning regimen prior to autologous stem cell transplant, since its introduction in 1992. We used a more aggressive alkylator-based conditioning regimen in an attempt to ... [High-dose BCNU/Melphalan conditioning regimen before autologous stem cell multiple myeloma. December 2017 We retrospectively studied 340 fit patients with multiple myeloma (MM) who underwent autologous stem cell transplantation (ASCT). We hypothesized that progression-free survival (PFS) of older patients was non-inferior to that of younger patients after ASCT ... [Efficacy and safety of high-dose chemotherapy with autologous stem cell transplantation in senior versus younger adults with newly diagnosed multiple myeloma. ](/publication/1169768) [Full text](https://dx.doi.org/10.1002/hon.2379) [Link to \u00b7 November 2017 Treatment-related mortality (TRM) remains elevated in adult patients undergoing umbilical cord blood transplantation (UCBT), including an early rise in TRM suggestive of excessive toxicity associated with the standard myeloablative total body irradiation ( ... [Adult Umbilical Cord Blood Transplantation Using Myeloablative to item](https://www.ncbi.nlm.nih.gov/pubmed/28729147) Marrow Transplant \u00b7 July 2017 Delayed hematopoietic recovery contributes to increased infection risk following umbilical cord blood (UCB) transplantation. In a Phase 1 study, adult recipients of UCB stem cells cultured ex vivo for 3 weeks with nicotinamide (NiCord) had earlier median n ... [Transplantation of Ex Vivo Expanded Umbilical Cord Blood (NiCord) Decreases Early Infection and Hospitalization. ](/publication/1244141) [Full May 2017 OBJECTIVES: Multiple myeloma (MM) primarily strikes older adults, but chemotherapy such as bortezomib (Velcade), cyclophosphamide and dexamethasone (VCD) is often excessively toxic to very old or frail adults and those with substantial comorbidit ... [Phase II study of dose-attenuated bortezomib, (\"VCD-Lite\") in very old or with multiple myeloma. to item](https://www.ncbi.nlm.nih.gov/pubmed/28256432) Blood Marrow Transplant \u00b7 February 2017 Comprehensive recommendations for maintenance therapy after autologous stem cell transplantation (ASCT) for patients with multiple myeloma (MM) have yet to be defined. Bortezomib has been utilized as maintenance therapy after ASCT, but data attesting to th ... [Outcomes of Maintenance Therapy with Bortezomib after Autologous Stem Cell Transplantation for Patients text](https://dx.doi.org/10.1016/j.bbmt.2016.11.010) [Link to item](https://www.ncbi.nlm.nih.gov/pubmed/27856369) [Cite](/publication/1159255#cite) Infect Dis \u00b7 October 15, 2016 BACKGROUND: Respiratory viral infections (RVIs) are frequent complications of hematopoietic stem cell transplant (HSCT). Surgical masks are a simple and inexpensive intervention that may reduce nosocomial spread. METHODS: In this prospective single-center ... [Universal Mask Usage for Reduction of Respiratory Viral Infections After Stem Cell Transplant: A Prospective Trial. ](/publication/1138865) [Full \u00b7 August 17, 2016 BACKGROUND: The binding its ligand (stromal-derived factor-1) maintains hematopoietic stem/progenitor cells (HSPCs) in a quiescent state. We hypothesized that blocking CXCR4/SDF-1 interaction after hematopoietic stem cell \u00b7 June 2015 High-dose cyclophosphamide (Cy) is frequently employed for peripheral blood mobilization of hematopoietic stem cells before high-dose chemotherapy with autologous stem cell transplantation (ASCT) in multiple myeloma (MM). The benefit of mobilization with C ... [Cyclophosphamide-based hematopoietic stem cell mobilization before autologous stem cell in newly diagnosed multiple myeloma. ](/publication/1047351) \u00b7 February 2015 BACKGROUND: Peripheral blood stem cell (PBSC) rescue following myeloablative therapy is a mainstay of cancer therapy. To evaluate the ability of the Spectra Optia Apheresis System (SO), a newly developed apheresis device, the device was studied in multiple ... [Evaluation of the spectra Optia\u00ae mononuclear cell \u00b7 February 2015 BACKGROUND: The safety and feasibility of the symptom-limited cardiopulmonary exercise test (CPET) and the 6-minute walk test (6MWT) has not been rigorously tested in patients with multiple myeloma (MM) after high-dose chemotherapy with autologous stem cel ... [Quantitative measures of physical functioning after autologous hematopoietic stem cell transplantation in multiple myeloma: ](/publication/1053269) [Full text](https://dx.doi.org/10.1016/j.clml.2014.09.002) [Link to item](https://www.ncbi.nlm.nih.gov/pubmed/25445473) Journal Invest \u00b7 July 2014 BACKGROUND: Delayed hematopoietic recovery is a major drawback of umbilical cord blood (UCB) transplantation. Transplantation of ex vivo-expanded UCB shortens time to hematopoietic recovery, but long-term, robust engraftment by the expanded unit has yet to ... [Umbilical cord blood expansion Biol Blood Marrow Transplant \u00b7 February 2014 We present a comparative study on 124 patients with hematologic malignancies who had undergone reduced-intensity conditioning and then received a transplant from an HLA-matched related (MRD), an HLA-matched unrelated (MUD), or an ... [Reduced-intensity allogeneic transplantation using alemtuzumab from HLA-matched related, unrelated, [Link to item](https://www.ncbi.nlm.nih.gov/pubmed/24269380) [Cite](/publication/1000381#cite) Marrow Transplant \u00b7 July 2013 High fevers and/or rashes prior to neutrophil engraftment are frequently observed after umbilical cord blood (UCB) transplantation, and the condition is referred to as pre-engraftment syndrome (PES). Few studies have evaluated the risk factors for and trea ... [Pre-engraftment syndrome after myeloablative dual umbilical cord blood transplantation: risk factors and response Access](https://hdl.handle.net/https://hdl.handle.net/10161/24691) [Link to Cancer Invest \u00b7 March 2013 PURPOSE: This Phase I study assessed the feasibility of concomitant arsenic trioxide (ATO), ascorbic acid (AA), and bortezomib (Velcade) (AAV) for patients with relapsed/refractory multiple myeloma. EXPERIMENTAL DESIGN: ATO (0.25 mg/kg) and AA (1 g) were ... [A Phase I study of arsenic trioxide (Trisenox), ascorbic acid, and bortezomib (Velcade) \u00b7 November 2012 Immunologic reconstitution after allogeneic hematopoietic cell transplantation is a critical component of successful outcome. Umbilical cord blood (UCB) transplantation in adult recipients is associated with slow and often inadequate immune recovery. We ch ... [Immune recovery in adult patients after myeloablative dual umbilical cord blood, matched sibling, and matched unrelated donor hematopoietic cell transplantation. ](/publication/746088) [Full text](https://dx.doi.org/10.1016/j.bbmt.2012.06.005) [Link to item](https://www.ncbi.nlm.nih.gov/pubmed/22698485) [Cite](/publication/746088#cite) Journal Article Cancer November 2012 [Mini test dose of intravenous busulfan (busulfex(\u00ae)) in allogeneic Transplant \u00b7 October 2012 This prospective, randomized, double-blind, placebo-controlled study evaluated the efficacy of palifermin to reduce the incidence of severe (grade 3-4) acute GVHD after myeloablation and allo-SCT. for hematologic malignancies r ... \u00b7 October 2012 Autologous hematopoietic SCT (auto-HSCT) can be curative for patients with germ cell tumors. Poor stem cell mobilization jeopardizes the ability to deliver this therapy. Herein, we describe a retrospective study examining safety and efficacy of plerixafor ... [Efficacy and safety of hematopoietic stem cell remobilization with plerixafor+G-CSF in adult patients with cell tumors. ](/publication/752770) [Full text](https://dx.doi.org/10.1038/bmt.2012.21) [Link to item](https://www.ncbi.nlm.nih.gov/pubmed/22343676) [Cite](/publication/752770#cite) Journal Article Bone Marrow Transplant \u00b7 August 2012 Plerixafor, given on day 4 of G-CSF treatment is more effective than G-CSF alone in mobilizing hematopoietic progenitor cells. We tested a strategy of preemptive plerixafor use following assessment of the peak mobilization response to 5 days of G-CSF. Pati ... [Preemptive dosing of plerixafor given to poor day 5 G-CSF administration. ](/publication/764598) [Full text](https://dx.doi.org/10.1038/bmt.2011.217) [Link to item](https://www.ncbi.nlm.nih.gov/pubmed/22080963) [Cite](/publication/764598#cite) Journal Article Bone Marrow Transplant \u00b7 June 2012 The impact of activating KIR (aKIR) and inhibitory KIR (iKIR) on OS, relapse-related mortality (RRM) and acute GVHD (aGVHD) was prospectively studied in 84 adults with high-risk hematologic malignancies receiving reduced intensity conditioning (RIC) T-cell ... [Differential impact of inhibitory and activating Killer Ig-Like Receptors (KIR) on high-risk patients with myeloid and lymphoid malignancies undergoing reduced intensity transplantation [Full text](https://dx.doi.org/10.1038/bmt.2011.181) [Link to item](https://www.ncbi.nlm.nih.gov/pubmed/22139069) [Cite](/publication/764602#cite) Journal Article Bone Marrow Transplant \u00b7 May 2012 Primary graft failure after allogeneic hematopoietic cell transplantation is a life-threatening complication. A shortened conditioning regimen may reduce the risk of infection and increase the chance of survival. Here, we report the outcome of 11 patients ... [Outcomes of a 1-day nonmyeloablative salvage regimen for patients with primary graft failure after allogeneic hematopoietic cell transplantation. Journal Article Biol Marrow Transplant \u00b7 June 2011 High treatment-related mortality (TRM) and high graft failure rate are serious concerns in HLA-mismatched umbilical cord blood (UCB) transplantation with myeloablative conditioning. We conducted a prospective trial of dual UCB transplantation using modifie ... [Adult dual umbilical cord blood transplantation using myeloablative total body irradiation (1350 cGy) Biol Phys \u00b7 March 15, 2011 PURPOSE: To describe renal shielding techniques and dosimetry in delivering total body irradiation (TBI) to patients with severe systemic sclerosis (SSc) enrolled in a hematopoietic stem cell transplant protocol. METHODS AND MATERIALS: The Scleroderma: Cyc ... [Renal shielding and dosimetry for patients with severe systemic sclerosis receiving immunoablation with total body irradiation in the scleroderma: cyclophosphamide trial. ](/publication/721652) [Full text](https://dx.doi.org/10.1016/j.ijrobp.2010.05.036) [Link to [Cite](/publication/721652#cite) Journal Article Cancer Invest \u00b7 January 2011 INTRODUCTION: High relapse rates and infections remain primary causes of failure in nonmyeloablative transplantation. Interleukin-2 (IL-2) may stimulate the immune system and improve outcomes. The primary objective of this pilot study was to evaluate the f ... [Feasibility of low-dose interleukin-2 therapy following T-cell-depleted stem cell item](https://www.ncbi.nlm.nih.gov/pubmed/21166499) [Cite](/publication/743485#cite) Journal Article Biol Marrow Transplant \u00b7 August 2010 Infusing natural killer (NK) cells following transplantation may allow less infections and relapse with little risk of acute graft-versus-host disease (aGVHD). We delivered 51 total NK lymphocyte infusions HLA matched family ](/publication/743059) [Full text](https://dx.doi.org/10.1016/j.bbmt.2010.02.018) [Link to item](https://www.ncbi.nlm.nih.gov/pubmed/20188202) [Cite](/publication/743059#cite) Journal Article Cancer Invest \u00b7 July 2010 We present a study of the prevalence of genetic polymorphisms and expression of genes encoding the drug-resistance proteins glutathione S-transferases (GSTs) in order to gain insights into the pattern of failure evident in mantle cell lymphoma. We note a h ... [Overcoming drug resistance in mantle cell lymphoma using a combination of dose-dense and intense therapy. text](https://dx.doi.org/10.3109/07357901003631015) [Link to item](https://www.ncbi.nlm.nih.gov/pubmed/20521909) [Cite](/publication/757357#cite) Journal Article Biol Blood Marrow Transplant \u00b7 January 2010 The purpose of this study was to evaluate the efficacy and safety of short-course bortezomib, melphalan, prednisone (VMP) in previously untreated multiple myeloma as frontline therapy for transplant-ineligible patients and induction and prednisone as induction prior to transplant or as frontline therapy for nontransplant candidates in patients with previously untreated multiple myeloma. ](/publication/757585) [Full text](https://dx.doi.org/10.1016/j.bbmt.2009.08.017) [Link to item](https://www.ncbi.nlm.nih.gov/pubmed/19733251) [Cite](/publication/757585#cite) Journal Article Bone Marrow Transplant \u00b7 February 2009 We report the outcome of early donor lymphocyte infusions (DLIs) after T-cell depleted non-myeloablative transplantation using stem cells from HLA-matched or mismatched donors. Sixty-nine patients with high-risk hematologic malignancies received DLI follow item](https://www.ncbi.nlm.nih.gov/pubmed/18850014) [Cite](/publication/764635#cite) Journal Article Biol Blood Marrow Transplant \u00b7 May 2008 The efficacy of once-daily intravenous busulfan with fludarabine as a preparative regimen for partially matched umbilical cord blood transplantation has not been formally studied. We randomized 10 adult patients with myeloid malignancies to receive either ... [Myeloablative intravenous busulfan/fludarabine conditioning does not facilitate reliable engraftment of dual umbilical cord blood grafts in adult recipients. ](/publication/764639) [Full text](https://dx.doi.org/10.1016/j.bbmt.2008.02.016) [Link to item](https://www.ncbi.nlm.nih.gov/pubmed/18410902) [Cite](/publication/764639#cite) Journal Article Bone Marrow Transplant \u00b7 January 2008 Following initial graft rejection, a second attempt at allogeneic immunotherapy is often contemplated, but data on the success is limited. We therefore report on 11 patients with hematologic malignancies, renal cell cancer or marrow failure who underwent a ... [Outcomes of a second non-myeloablative allogeneic stem cell rejection. [Link to item](https://www.ncbi.nlm.nih.gov/pubmed/17982503) [Cite](/publication/764645#cite) Journal Article Biol Blood Marrow Transplant \u00b7 December 2007 End-organ damage is common in patients with sickle cell disease (SCD) thereby limiting the use of allogeneic stem cell transplantation (SCT). We report the outcome of 2 adult SCD patients, 1 with end-stage renal disease (ESRD), who underwent fludarabine-ba ... [Fludarabine-based nonmyeloablative stem cell transplantation for sickle cell disease with and without renal failure: clinical outcome and pharmacokinetics. ](/publication/764649) June 2007 The Digene Hybrid Capture system (CMV) DNA and plasma specimens collected from allogeneic ... [Comparison of the Digene Hybrid Capture ](/publication/733707) [Full \u00b7 February 20, 2007 PURPOSE: Allogeneic transplantation is typically limited to younger patients having a matched donor. To allow a donor to be found for nearly all patients, we have used a nonmyeloablative conditioning regimen in conjunction with stem cells from a related do ... [Partially matched, nonmyeloablative item](https://www.ncbi.nlm.nih.gov/pubmed/17228020) [Cite](/publication/719137#cite) Lab Med \u00b7 October 2006 CONTEXT: Nonmyeloablative stem cell transplantation (NMSCT) is a mode of immunotherapy increasingly employed in treating hematologic, lymphoid, and solid tumors. Patients are monitored principally by molecular analysis of donor engraftment. OBJECTIVE: To d ... [Morphologic examination of sequential bone marrow biopsies after nonmyeloablative stem cell transplantation complements molecular studies of donor engraftment. ](/publication/719136) [Full text](https://dx.doi.org/10.5858/2006-130-1479-MEOSBM) [Link to item](https://www.ncbi.nlm.nih.gov/pubmed/17090189) [Cite](/publication/719136#cite) Journal Article Transplantation \u00b7 September 27, 2005 The clinical impact of voriconazole resistance in Candida glabrata is not well described. Five hematopoietic stem cell transplant recipients that developed breakthrough Candida glabrata bloodstream infections while receiving voriconazole are described and ... [Candida glabrata Article Biol Blood Marrow Transplant \u00b7 August 2004 We report the outcome of 13 patients with advanced malignancies who underwent nonmyeloablative conditioning therapy followed by infusion of partially matched unrelated cord blood cells. The median age of these patients was 49 years, and their median weight ... [Adult recipients of umbilical cord Cancer \u00b7 June 1, 2004 BACKGROUND: Many patients with recurrent, intermediate or high-grade non-Hodgkin lymphoma (NHL) may not respond to or are not candidates for aggressive salvage chemotherapy. Effective, less toxic regimens are needed. Although high-dose taxanes have not bee ... Biol Blood Marrow Transplant \u00b7 December 2003 Since January 1996, we have administered myeloablative therapy followed by infusion of unrelated umbilical cord blood cells in 57 adult patients with high-risk disease. The median age was 31 years (range, 18-58 years), and the median weight was 70 kg (rang ... [Unrelated umbilical cord blood transplantation in adult patients. text](https://dx.doi.org/10.1016/j.bbmt.2003.08.007) [Link to item](https://www.ncbi.nlm.nih.gov/pubmed/14677117) [Cite](/publication/665912#cite) Journal Article Biol Blood Marrow Transplant \u00b7 March 2003 We have performed a phase I dose escalation of 4-Hydroperoxycyclophosphamide (4HC) purging of autologous peripheral blood progenitor cells (PBPCs) to improve the outcome of autologous transplantation for patients with myeloid leukemia. Peripheral blood ste ... [4-hydroperoxycyclophosphamide--purged peripheral blood stem cells for autologous transplantation in patients with acute myeloid leukemia. [Link to item](https://www.ncbi.nlm.nih.gov/pubmed/12652469) Clin Cancer Res \u00b7 February 2003 PURPOSE: The purpose of this study was to determine the maximum tolerated duration of infusion of gemcitabine at 10 mg/m(2)/min in combination with fludarabine at 25 mg/m(2) daily for 5 days in the treatment of relapsed or refractory acute myelogenous leuk ... [Phase I Leuk Lymphoma \u00b7 May 2002 Twenty-three adult patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or prolymphocytic leukemia (PLL) were treated for up to 12 weeks with the anti-CD52 monoclonal antibody alemtuzumab. Patients were a median of six years from diagnos ... [Alemtuzumab in relapsed or [Cite](/publication/689897#cite) Cytokine April 7, 2002 Treatment with myeloablative chemotherapy and autologous peripheral blood stem cell (PBSC) transplantation followed by vaccination with autologous dendritic cells (DCs) treated with tumor antigens is a promising therapeutic strategy for several types of ca ... [Mobilization of dendritic cells from patients with breast cancer into peripheral blood stem cell leukapheresis samples using Flt-3-Ligand pulmonary edema (REPE) leading to hypoxic respiratory failure and death occurred following a unilateral low-volume (750 ml) thoracentesis in a young patient 8 days after high-dose chemotherapy and autologous stem cell transplantation (HDC/ASCT ... [Fatal re-expansion pulmonary edema associated with increased lung IL-8 levels following high-dose chemotherapy and autologous to item](https://www.ncbi.nlm.nih.gov/pubmed/12169751) Journal Article Transplant \u00b7 2002 T-cell recovery following myeloablative preparatory regimens and cord blood transplantation in adult patients gen erally occurs between 1 and 3 years following allogeneic bone marrow transplantation. T-cell reconstitution may involve thymic education of do ... [Nonmyeloablative regimen preserves \"niches\" allowing peripheral [Link to item](https://www.ncbi.nlm.nih.gov/pubmed/12064361) [Cite](/publication/689919#cite) Journal Article Biol Blood Marrow Transplant \u00b7 2002 Despite modern chemotherapy, advanced breast cancer remains a significant cause of cancer morbidity and mortality in women. Patients with disease involvement of multiple lymph nodes represent a subgroup with a high risk of relapse. In particular, 50% of pa ... [High-dose chemotherapy and hematopoietic support for patients with high-risk primary breast cancer and involvement of 4 to 9 lymph nodes. ](/publication/764676) [Full text](https://dx.doi.org/10.1053/bbmt.2002.v8.abbmt080666) [Link to item](https://www.ncbi.nlm.nih.gov/pubmed/12523579) [Cite](/publication/764676#cite) Journal Article Blood \u00b7 December 1, 2001 Reduction in the toxicity of allogeneic transplantation with nonmyeloablative induction regimens has expanded the scope of practice to older and more debilitated patients. However, the limited availability of matched sibling donors requires that alternativ ... [Successful allogeneic engraftment of ](/publication/689904) [Full text](https://dx.doi.org/10.1182/blood.v98.12.3486) [Link to 1, 2001 ABX-CBL, an immunoglobulin M murine monoclonal antibody, recognizes CD147 cell killing through complement-mediated lysis. In a dose-finding trial, 27 patients with disease ABX-CBL Article Bone Marrow Transplant \u00b7 September 2001 [Rhizopus presenting as an endobronchial obstruction following bone marrow transplant. ](/publication/785354) [Full text](https://dx.doi.org/10.1038/sj.bmt.1703191) [Link to item](https://www.ncbi.nlm.nih.gov/pubmed/11607783) [Cite](/publication/785354#cite) Journal Article Bone Marrow Transplant \u00b7 May 2001 Antineoplastic therapy can be associated with drug-induced lung toxicity. With the increasing use of amiodarone for cardiac dysrhythmias there is an increasing possibility of its combined use with chemotherapies for various malignancies. We report a patien ... [Amiodarone text](https://dx.doi.org/10.1038/sj.bmt.1703039) [Link to item](https://www.ncbi.nlm.nih.gov/pubmed/11438830) [Cite](/publication/646857#cite) Journal Article Blood \u00b7 January 15, 2001 Advanced stage follicular small cleaved and mixed cell lymphoma is characterized by relapse from remission and survival ranging from 6 to 12 years. Because young patients have the greatest compromise in longevity, the efficacy and toxicity of high-dose rad ... [High-dose therapy and autologous bone marrow transplantation for follicular lymphoma in first complete or partial remission: results of a phase II clinical trial. ](/publication/639545) [Full text](https://dx.doi.org/10.1182/blood.v97.2.404) [Link to item](https://www.ncbi.nlm.nih.gov/pubmed/11154216) [Cite](/publication/639545#cite) 2001 (cyclophosphamide, carmustine, and etoposide) in combination with autologous HCT achieves survival rates of approximately 50% at 5 years in recurrent or refractory Hodgkin's disease (HD). However, carmustine (BCNU) dose-dependent [Efficacy and toxicity CCNU-containing high-dose chemotherapy regimen followed by autologous hematopoietic cell Biol Blood Marrow Transplant \u00b7 2001 PURPOSE: To evaluate the efficacy of inhaled fluticasone propionate (Flovent) as prophylaxis against delayed pulmonary toxicity syndrome (DPTS) and decline in pulmonary function in breast cancer patients undergoing high-dose chemotherapy with the condition ... [Inhaled steroids as prophylaxis for delayed pulmonary toxicity syndrome in breast cancer patients undergoing high-dose chemotherapy and autologous stem cell transplantation. to item](https://www.ncbi.nlm.nih.gov/pubmed/11400949) [Cite](/publication/764681#cite) Journal Article Biol Blood Marrow Transplant \u00b7 2000 Central nervous system (CNS) involvement by non-Hodgkin's lymphoma (NHL) carries a poor patient prognosis whether it occurs as a primary site of disease or secondarily in patients with systemic disease. In a group of 481 patients undergoing high-dose thera ... [High-dose therapy with hematopoietic cell transplantation for patients with central nervous system involvement non-Hodgkin's lymphoma. Biol Blood Marrow Transplant \u00b7 2000 We have previously demonstrated a decrease in the incidence of acute graft-versus-host disease (GVHD) with the addition of methotrexate (MTX) to cyclosporine (CSP) and prednisone (PSE) chemotherapy in patients with leukemia. We have now completed a prospec ... [Equivalence of 2 effective graft-versus-host disease high-dose therapy with autologous hematopoietic progenitor cell (AHPC) support has been used to deliver dose-intensive therapy. We have used this approach as well as single-cycle high-dose therapy in treating patients with metastatic breast ... high-dose therapy with hematopoietic support for metastatic breast cancer: no improvement in Article Biol Blood Marrow Transplant \u00b7 2000 Our purpose was to evaluate the outcome and costs of high-dose chemotherapy and autologous peripheral blood progenitor cell (PBPC) transplantation in patients with the inability to mobilize sufficient numbers of PBPCs to allow rapid engraftment after PBPC ... [Favorable treatment outcome in non-Hodgkin's lymphoma to item](https://www.ncbi.nlm.nih.gov/pubmed/11063379) Clin Cancer Res \u00b7 November 1999 Dose-intensive chemotherapy appears to be important in the treatment of patients with recurrent solid tumors. Expanding upon our prior experience, we report the results of our most recent approach to administering dose-intensive therapy using four cycles o ... [A feasibility study of multiple cycle therapy with melphalan, thiotepa, and paclitaxel followed by mitoxantrone, item](https://www.ncbi.nlm.nih.gov/pubmed/10589752) [Cite](/publication/639566#cite) Journal Article J Clin Oncol \u00b7 October 1999 PURPOSE: We performed a retrospective review to determine predictive and prognostic factors in patients with metastatic breast cancer who received induction therapy, and, if they responded to treatment, high-dose chemotherapy. PATIENTS AND METHODS: Patient ... [Prognostic and predictive factors for patients with metastatic breast cancer undergoing aggressive induction therapy followed by item](https://www.ncbi.nlm.nih.gov/pubmed/10506601) Article Blood \u00b7 April 15, 1999 This randomized study compared the number of leukaphereses required to collect an optimal target yield of 5 x 10(6) CD34(+) peripheral blood progenitor cells/kg, using either stem cell factor (SCF) at 20 micrograms/kg/d in combination with Filgrastim at 10 ... [A randomized phase 3 study of peripheral blood progenitor cell mobilization with stem cell factor and filgrastim in high-risk breast cancer patients. ](/publication/785355) [Link to item](https://www.ncbi.nlm.nih.gov/pubmed/10194427) [Cite](/publication/785355#cite) Journal Article Biol Blood Marrow Transplant \u00b7 1999 Graft-vs.-host disease (GVHD) is a major predictor of outcome following allogeneic bone marrow transplantation (BMT). For patients alive at day 100 after BMT, the presence or absence of chronic GVHD is one of the most important determinants of survival and ... [Cyclosporine, methotrexate, and prednisone compared with cyclosporine and prednisone for prevention of acute graft-vs.-host disease: effect on chronic graft-vs.-host disease text](https://dx.doi.org/10.1016/s1083-8791(99)70003-0) [Link to item](https://www.ncbi.nlm.nih.gov/pubmed/10534058) [Cite](/publication/639502#cite) Journal Article Biol Blood Marrow Transplant \u00b7 December 1997 Myeloablative therapy followed by allogeneic bone marrow transplantation (BMT) has proven to be curative therapy in patients with hematologic malignancies. Relapse, however, remains a major cause of treatment failure for patients with advanced disease. Dur ... [Fractionated total-body irradiation, etoposide, and cyclophosphamide followed by allogeneic bone marrow transplantation for patients with or advanced-stage Oncol \u00b7 May 1997 Renal cell carcinoma remains a major challenge for urologic oncologists. Over the past year, progress has been made in understanding the molecular biology of this disease and in describing new prognostic factors for outcome following nephrectomy. Studies h to item](https://www.ncbi.nlm.nih.gov/pubmed/9229154) [Cite](/publication/785357#cite) Journal Article Blood \u00b7 February 1, 1997 One hundred nineteen patients with relapsed or refractory Hodgkin's disease (HD) received high-dose therapy followed by autologous hematopoietic progenitor cell transplantation. Three preparatory regimens, selected on the basis of prior therapy and pulmona ... [High-dose therapy and autologous recurrent or refractory Hodgkin's disease: analysis of the Stanford University results and prognostic indices. ](/publication/639574) [Link to item](https://www.ncbi.nlm.nih.gov/pubmed/9028311) [Cite](/publication/639574#cite) Journal Article J Clin Oncol \u00b7 January 1997 PURPOSE: To determine the effect of age on the outcome of autologous bone marrow transplantation (ABMT) and/or peripheral-blood progenitor-cell (PBPC) transplantation. PATIENTS AND METHODS: A retrospective analysis was performed on 500 consecutive patients ... [Influence of age on the outcome of 500 autologous bone marrow transplant procedures [Link to item](https://www.ncbi.nlm.nih.gov/pubmed/8996120) Am \u00b7 1997 PURPOSE: Lymphomas of the paranasal sinuses may have poorer prognoses compared with other extranodal lymphomas of the head and neck, and are not well defined as a particular clinicopathologic entity. The outcome of combined-modality therapy and central ner ... [Non-Hodgkin's lymphoma of the paranasal sinuses: clinical to combined-modality therapy. ](/publication/785356) [Link to item](https://www.ncbi.nlm.nih.gov/pubmed/9327155) [Cite](/publication/785356#cite) Journal Article Cancer \u00b7 December 15, 1996 BACKGROUND: A number of studies have demonstrated that high dose chemotherapy, with or without radiotherapy, with autologous marrow and/or peripheral blood progenitor cell support can result in improved overall and complete response rates in patients with ... [High dose etoposide-based myeloablative therapy followed by autologous blood progenitor cell rescue the treatment text](https://dx.doi.org/10.1002/(sici)1097-0142(19961215)78:12<2502::aid-cncr9>3.0.co;2-l) [Link to item](https://www.ncbi.nlm.nih.gov/pubmed/8952558) [Cite](/publication/639561#cite) Blood Marrow Transplant \u00b7 May 1996 Thalidomide has been reported to be an effective agent for the treatment of chronic graft-vs.-host disease (GVHD). To determine its efficacy as a prophylactic agent for the prevention of chronic GVHD, a prospective randomized double-blind study was perform ... to item](https://www.ncbi.nlm.nih.gov/pubmed/9118303) [Cite](/publication/639532#cite) Journal Article Biol Blood Marrow Transplant \u00b7 May 1996 The use of high-dose chemotherapy with or without total-body irradiation (TBI) followed by autologous hematopoietic cell transplantation is associated with improved survival for relapsed or refractory non-Hodgkin's lymphoma (NHL). Previous reports comparin ... [Influence of preparatory regimen and source of hematopoietic on outcome of autotransplantation for non-Hodgkin's A non-radiation-containing regimen of busulfan and cyclophosphamide (BU/CY) was evaluated for toxicity, relapse, and long-term survival in patients who received allogeneic bone marrow transplantation (BMT) for myelodysplasia (MDS). PATIENTS AND ME ... [Busulfan/cyclophosphamide as conditioning regimen bone ](/publication/764688) [Full text](https://dx.doi.org/10.1200/JCO.1995.13.12.2973) [Link to item](https://www.ncbi.nlm.nih.gov/pubmed/8523063) [Cite](/publication/764688#cite) Journal Article Blood \u00b7 November 1, 1995 Thalidomide has been reported to be an effective agent for treatment of chronic graft-versus-host disease (CGVHD). To determine the efficacy of this agent in patients with refractory CGVHD a total of 80 patients who failed to respond to prednisone (PSE) or ... [Thalidomide as salvage therapy for chronic graft-versus-host disease. ](/publication/764689) [Link to item](https://www.ncbi.nlm.nih.gov/pubmed/7579470) [Cite](/publication/764689#cite) Journal Article Cancer \u00b7 September 1, 1995 BACKGROUND: Retrospective studies suggest that dose intensity is an important determinant of outcome in the treatment of patients with a variety of malignant diseases such as breast cancer, ovarian cancer, and lymphoma. Unfortunately, these results have no ... [Multiple cycles of high dose chemotherapy supported by hematopoietic progenitor cells as treatment for patients Forum \u00b7 September 1995 PURPOSE/OBJECTIVES: To explain the rationale and process of outpatient critical pathway development for sequential high-dose chemotherapy followed by peripheral blood stem cell transplantation. DATA SOURCES: Published books and journal articles. DATA SYNTH ... [Critical pathway for administering high-dose chemotherapy followed by peripheral blood stem cell rescue in the outpatient setting. ](/publication/785358) [Link to item](https://www.ncbi.nlm.nih.gov/pubmed/8532546) [Cite](/publication/785358#cite) Journal Article Blood \u00b7 June 1, 1995 High-dose chemotherapy with or without radiotherapy followed by autologous transplantation of hematopoietic progenitor cells is an effective treatment for patients with high-risk or relapsed non-Hodgkin's lymphoma. Chemotherapy and/or hematopoietic growth ... [Transplantation of enriched and purged peripheral blood progenitor cells from a single apheresis product in patients with non-Hodgkin's lymphoma. ](/publication/639554) [Link to item](https://www.ncbi.nlm.nih.gov/pubmed/7538824) [Cite](/publication/639554#cite) Journal Article Cancer \u00b7 March 15, 1995 BACKGROUND: This trial studied the feasibility and efficacy of a new preparatory regimen for autologous bone marrow transplantation for patients with advanced lymphoid malignancies. METHODS: Twenty-one patients with Hodgkin's disease (n = and non-Hodgk ... [A new preparatory regimen for autologous bone with lymphoma. ](/publication/639567) [Full text](https://dx.doi.org/10.1002/1097-0142(19950315)75:6<1354::aid-cncr2820750618>3.0.co;2-m) [Link to item](https://www.ncbi.nlm.nih.gov/pubmed/7882286) [Cite](/publication/639567#cite) Journal Article Bone Marrow Transplantation \u00b7 January 1, 1995 The use of high-dose chemotherapy with bone marrow transplantation is becoming easier to administer because of improved supportive care techniques and is being increasingly utilized for patients with high-risk primary breast cancer. We report here survey d ... [Autologous bone marrow transplantation in primary breast cancer: The American experience ](/publication/785359) [Cite](/publication/785359#cite) Journal Article J Clin Oncol \u00b7 December 1994 PURPOSE: High-dose etoposide was incorporated regimen irradiation (FTBI) and high-dose cyclophosphamide before autologous transplant with the goal to enhance the antitumor effect of the myeloablative regimen in poor-risk Blood \u00b7 September 1, 1994 Ninety-four consecutive patients with chronic myelogenous leukemia in first clinical chronic phase, median age of 34.0 years (range, 6.8 to 52.4 years), with a histocompatible sibling donor, were treated with fractionated total body cGy) ... [Fractionated total-body irradiation and high-dose etoposide as a preparatory regimen for bone marrow transplantation for 94 patients with chronic myelogenous leukemia in chronic phase ](/publication/1302278) [Full text](https://dx.doi.org/10.1182/blood.v84.5.1672.bloodjournal8451672) [Cite](/publication/1302278#cite) Journal Article Blood \u00b7 September 1, 1994 Hematopoietic growth factors have been shown to be effective in reducing the period of neutropenia after autologous bone marrow transplantation (BMT). Initial concerns over potential aggravation of graft-versus-host disease (GVHD) and increase in the incid ... [Link to item](https://www.ncbi.nlm.nih.gov/pubmed/7520782) [Cite](/publication/639573#cite) Journal Article Blood \u00b7 September 1, 1994 Ninety-four consecutive patients with chronic myelogenous leukemia in first clinical chronic phase, median age of 34.0 years (range, 6.8 to 52.4 years), with a histocompatible sibling donor, were treated with fractionated total body cGy) ... [Fractionated total-body irradiation and high-dose etoposide as a preparatory regimen for bone marrow transplantation for 94 patients with chronic myelogenous leukemia in chronic phase. ](/publication/639579) [Link to item](https://www.ncbi.nlm.nih.gov/pubmed/8068956) [Cite](/publication/639579#cite) Journal Article Blood \u00b7 May 15, 1994 Anemia is a universal finding in patients undergoing autologous bone marrow transplantation (BMT). Effective therapies to increase the number of autologous red blood cells could result in a lower morbidity and mortality associated with red blood cell trans ... [A randomized study of erythropoietin and granulocyte colony-stimulating factor (G-CSF) versus placebo and G-CSF for patients with Hodgkin's and non-Hodgkin's lymphoma marrow transplantation. ](/publication/639585) [Link to item](https://www.ncbi.nlm.nih.gov/pubmed/7514046) [Cite](/publication/639585#cite) Journal Article Bone Marrow Transplant \u00b7 1994 In 1983, we began a series of clinical trials with the goal of reducing the relapse rate following allogeneic BMT for hematologic malignancies. Because of its anti-leukemic activity, the drug VP-16 was chosen and combined with total body irradiation (TBI). ... [Role of etoposide (VP-16) in preparatory regimens for patients with leukemia or lymphoma undergoing allogeneic bone marrow transplantation. ](/publication/639583) [Link to item](https://www.ncbi.nlm.nih.gov/pubmed/7728133) [Cite](/publication/639583#cite) Journal Article Blood \u00b7 November 1, 1993 Ninety-nine consecutive patients with acute leukemia in first complete remission under age 50 (median age 27 years; age range 1 to 47 years) with a histocompatible sibling donor were treated with fractionated total body irradiation (1,320 cGy) and high-dos ... [Fractionated total body irradiation and high-dose etoposide as a preparatory regimen for bone marrow transplantation for 99 patients with acute leukemia in first complete remission. ](/publication/639528) [Link to item](https://www.ncbi.nlm.nih.gov/pubmed/8219241) [Cite](/publication/639528#cite) Journal Article N Engl J Med \u00b7 October 21, 1993 BACKGROUND: Acute graft-versus-host disease (GVHD) following allogeneic bone marrow transplantation remains a serious problem. In a clinical trial, we tested the combination of cyclosporine and prednisone with and without methotrexate for the prevention of ... [Cyclosporine, methotrexate, and prednisone compared with cyclosporine to [Cite](/publication/639550#cite) Journal Article Leukemia \u00b7 October 1993 Cloned colony-stimulating factors have been shown to accelerate myeloid recovery following autologous bone marrow transplantation. Studies with granulocyte-macrophage colony-stimulating factor (GM-CSF) have demonstrated efficacy in accelerating [The efficacy of granulocyte colony-stimulating factor marrow transplantation for non-Hodgkin's lymphoma with monoclonal antibody purged bone marrow. ](/publication/639563) [Link to item](https://www.ncbi.nlm.nih.gov/pubmed/7692189) [Cite](/publication/639563#cite) Journal Article Blood \u00b7 April 15, 1993 Hematopoietic growth factors have been used to accelerate engraftment after bone marrow transplantation and to \"mobilize\" peripheral blood progenitor cells (PBPC). We report on the data in 85 consecutive patients with Hodgkin's disease who were treated in ... [Granulocyte colony-stimulating factor \"mobilized\" peripheral blood progenitor high-dose chemotherapy. ](/publication/639542) [Link to item](https://www.ncbi.nlm.nih.gov/pubmed/7682454) [Cite](/publication/639542#cite) Journal Article Blood \u00b7 January 15, 1993 Current intensive chemotherapy for acute nonlymphoblastic leukemia (ANLL) results in a complete remission in the majority of patients. Unfortunately, the duration of remission is short and most of the patients will experience a relapse of their underlying ... [Busulfan/etoposide--initial experience with a new preparatory regimen for autologous bone marrow transplantation in patients with acute nonlymphoblastic leukemia. ](/publication/639516) [Link to item](https://www.ncbi.nlm.nih.gov/pubmed/8422458) [Cite](/publication/639516#cite) Journal Article Blood \u00b7 August 1, 1992 To determine the quality of life in adult patients after autologous bone marrow transplantation (BMT), we administered a questionnaire to a cohort of patients seen at a single referral-based center. The sample included adults 18 years and older during the ... [Dynamic assessment of quality of life after autologous bone marrow transplantation. ](/publication/639497) [Link to item](https://www.ncbi.nlm.nih.gov/pubmed/1638031) [Cite](/publication/639497#cite) Journal Article Bone Marrow Transplant \u00b7 July 1992 To determine the potential impact of recombinant human erythropoietin (EPO) therapy in patients undergoing autologous bone marrow transplantation (BMT) and colony-stimulating factor therapy, we assayed endogenous serum EPO levels and noted blood transfusio ... [Serum erythropoietin levels and blood component therapy after autologous bone marrow transplantation: implications for erythropoietin therapy in this setting. ](/publication/785360) [Link to item](https://www.ncbi.nlm.nih.gov/pubmed/1515882) [Cite](/publication/785360#cite) Journal Article Lancet \u00b7 June 6, 1992 [G-CSF and peripheral blood progenitor cells. ](/publication/639519) [Link to item](https://www.ncbi.nlm.nih.gov/pubmed/1375969) Journal Article J Clin Oncol \u00b7 September 1991 Alkylating agents used either with or without radiation therapy have been associated with the development of myelodysplastic syndrome (MDS) and acute nonlymphoblastic leukemia (ANLL) after treatment of both malignant and nonmalignant disorders. This report ... [Importance of bone marrow cytogenetic evaluation before autologous [Full text](https://dx.doi.org/10.1200/JCO.1991.9.9.1575) [Link to item](https://www.ncbi.nlm.nih.gov/pubmed/1875219) [Cite](/publication/639555#cite) Journal Article Ann Intern Med \u00b7 January 15, 1991 [Corticosteroid therapy for diffuse alveolar hemorrhage in autologous to 1991 Seventy-seven disease and non-Hodgkin's lymphoma (NHL) patients received high-dose etoposide in combination with cyclophosphamide and either fractionated total body irradiation (TBI) (n = 28) or carmustine (n = 49) prior to autologous bone marrow ... Stanford experience with high-dose regimens marrow Allogeneic and autologous BMTs are highly effective and successful treatment modalities for selected patients. Use of BMT earlier in the course of disease yields better results when compared to patients with more advanced disease. Recent advances such as u ... [Bone marrow transplantation for hematologic malignancies: the Stanford [Link to item](https://www.ncbi.nlm.nih.gov/pubmed/2103141) [Cite](/publication/639500#cite) Journal Article J Immunol \u00b7 neutrophils. ](/publication/785363) [Link to item](https://www.ncbi.nlm.nih.gov/pubmed/6286768) [Cite](/publication/785363#cite) Journal Article Clinical Research \u00b7 January 1, 1982 of luminol enhancement of neutrophil chemiluminescence (CL) ](/publication/785361) Article Blood \u00b7 March 1981 The bioflavinoid quercetin was found to exert at least three separate effects on human polymorphonuclear leukocytes. (1) Concentrations of approximately 100 microM inhibited the adenosine to item](https://www.ncbi.nlm.nih.gov/pubmed/6450623) [Cite](/publication/785362#cite) 1979 [Distinction "}